Phase 3 study finds fezolinetant reduces the frequency and severity of menopausal hot flashes
Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday ...
Jun 11, 2022
0
17